BIOMAT Database Logo BIOMAT Database Logo

Single dose and steady-state pharmacokinetics of 4 mg and 8 mg oral salbutamol controlled-release in patients with bronchial asthma. 1989

B J Lipworth, and R A Clark, and D P Dhillon, and M K Charter, and J B Palmer, and D G McDevitt
Department of Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee, UK.

Fifteen patients with asthma were given salbutamol controlled-release (SCR) 4 mg or 8 mg twice daily for seven days, in a randomised double-blind cross-over design. Plasma salbutamol levels were measured after the first and fifteenth doses for a 12 h period following drug ingestion. At steady-state the geometric mean values for Cmax were 8.2 ng/ml for 4 mg, and 16.1 ng/ml for 8 mg. Median tmax values were 300 and 240 min respectively. The geometric mean AUC (0-12) were 4507 ng.min.ml-1 and 8980 ng.min/ml. Peak to trough fluctuation ratios were 0.577 and 0.572. There were no significant differences between 4 mg or 8 mg formulations, for any of the parameters measured, after appropriate corrections for dose. The concentration-time profiles at steady-state showed little fluctuation in plasma salbutamol levels over the twelve hour dosing interval. These results show that 4 mg and 8 mg formulations of SCR provide smooth plasma profiles at steady-state with a twice daily dosing regime.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D005541 Forced Expiratory Volume Measure of the maximum amount of air that can be expelled in a given number of seconds during a FORCED VITAL CAPACITY determination . It is usually given as FEV followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity. Forced Vital Capacity, Timed,Timed Vital Capacity,Vital Capacity, Timed,FEVt,Capacities, Timed Vital,Capacity, Timed Vital,Expiratory Volume, Forced,Expiratory Volumes, Forced,Forced Expiratory Volumes,Timed Vital Capacities,Vital Capacities, Timed,Volume, Forced Expiratory,Volumes, Forced Expiratory
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000420 Albuterol A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol. Salbutamol,2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol,Albuterol Sulfate,Proventil,Sultanol,Ventolin
D001249 Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). Asthma, Bronchial,Bronchial Asthma,Asthmas

Related Publications

B J Lipworth, and R A Clark, and D P Dhillon, and M K Charter, and J B Palmer, and D G McDevitt
Pharmacokinetics of oral salbutamol controlled-release in Asian patients with asthma.
January 1991, European journal of clinical pharmacology,
B J Lipworth, and R A Clark, and D P Dhillon, and M K Charter, and J B Palmer, and D G McDevitt
Single-dose and steady-state effects of controlled-release salbutamol on drug level and airflow obstruction in patients with asthma.
August 1992, Singapore medical journal,
B J Lipworth, and R A Clark, and D P Dhillon, and M K Charter, and J B Palmer, and D G McDevitt
Single intravenous dose and steady-state oral dose pharmacokinetics of nicardipine in healthy subjects.
January 1987, Biopharmaceutics & drug disposition,
B J Lipworth, and R A Clark, and D P Dhillon, and M K Charter, and J B Palmer, and D G McDevitt
Steady-state pharmacokinetics of controlled release oral morphine sulphate in healthy subjects.
January 1986, Clinical pharmacokinetics,
B J Lipworth, and R A Clark, and D P Dhillon, and M K Charter, and J B Palmer, and D G McDevitt
[Treatment of bronchial asthma in winter using controlled-release salbutamol].
January 1990, Revista alergia Mexico,
B J Lipworth, and R A Clark, and D P Dhillon, and M K Charter, and J B Palmer, and D G McDevitt
Oral salbutamol in bronchial asthma.
April 1974, The Indian journal of chest diseases,
B J Lipworth, and R A Clark, and D P Dhillon, and M K Charter, and J B Palmer, and D G McDevitt
Single-dose and steady-state pharmacokinetics of aminoglutethimide.
January 1985, Clinical pharmacokinetics,
B J Lipworth, and R A Clark, and D P Dhillon, and M K Charter, and J B Palmer, and D G McDevitt
Steady state pharmacokinetics of conventional versus controlled-release carbamazepine in patients with epilepsy.
March 1993, Epilepsy research,
B J Lipworth, and R A Clark, and D P Dhillon, and M K Charter, and J B Palmer, and D G McDevitt
Single dose and steady-state pharmacokinetics of adinazolam after oral administration to man.
January 1987, Biopharmaceutics & drug disposition,
B J Lipworth, and R A Clark, and D P Dhillon, and M K Charter, and J B Palmer, and D G McDevitt
Comparison between oral procaterol and salbutamol in patients with bronchial asthma.
January 1988, Current medical research and opinion,
Copied contents to your clipboard!